TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00822705

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Control arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablet
Description: Control arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablet
Description: Control arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablet
Description: Control arm
Study: NCT02279771

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transanal anastomotic reinforcement
Description: a circular anal dilator (CAD) of 34mm in diameter will be introduced into the anus to facilitate the transanal introduction of the 29-31 circular stapler. The stapler shaft will be introduced trying to avoid the stapler line and connected with the anvil of the prepared proximal colon and then fired.~Patients selected on the TAR-LAR arm will have the stapled suture reinforced by 6 supplemental full thickness stitches in vycril 3/0 placed transanally with the aid of a semicircular valve introduced into the CAD (Epo Flier, SapiMed SPA, Alessandria, Italy), at hours 2-4-6-8-10-12.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: protective ileostomy group
Description: S-LAR patients will had a standard lateral protective ileostomy in the right iliac region or a colostomy in the left region.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a circular anal dilator (CAD)
Description: Epo Flier, SapiMed SPA, Alessandria, Italy
Study: NCT02558140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RO6874813
Description: RO6874813 at RP2D will be administered by IV infusion as per dosing schedule determined in Part 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RO6874813
Description: RO6874813 at RP2D will be administered by IV infusion as per dosing schedule determined in Part 1.
Study: NCT00823394

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Completed privately via computer at Windsor Village Church, approximately 75 minutes. Repeated at Months 12 and 24.

Intervention type: OTHER
Intervention: Body Measurements
Description: Waist, hip, height, and weight measured privately. Repeated at Months 12 and 24.

Intervention type: BEHAVIORAL
Intervention: Self-help Materials
Description: Information on how to lower risk for developing cancer.
Study: NCT03500627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-101
Description: Intravenous Injection of OP-101 in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-101
Description: Intravenous Injection of OP-101 in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-101
Description: Intravenous Injection of OP-101 in healthy volunteers.
Study: NCT01502449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DESTRESS-T
Description: Usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider, and care coordination

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Usual Care (OUC)
Description: Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
Study: NCT01499745

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Exercise Training in Pulmonary Rehabilitation Program:~12 weeks of 60 min exercise bout, twice a week at pulmonary rehabilitation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Exercise Training in Pulmonary Rehabilitation Program:~12 weeks of 60 min exercise bout, twice a week at pulmonary rehabilitation
Study: NCT04497805

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC-SHEET
Description: Hydrogel sheet containing Allogenic Mesenchymal Stem Cells

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ALLO-ASC-SHEET
Description: Hydrogel sheet containing Allogenic Mesenchymal Stem Cells
Study: NCT01023230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DV-601
Description: Six injections of DV-601 administered over a period of 12 weeks.
Study: NCT03909282

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumpectomy
Description: Standard of Care surgery for DCIS (either lumpectomy or mastectomy)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial breast irradiation prior to surgery
Description: Partial breast irradiation (PBI) will be delivered once aday for 5 days. The planned daily dose is 6 Gy prior to surgery (neo adjuvant)
Study: NCT00167596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Spectroscopy
Description: resuscitation will be based on Surviving Sepsis Campaign guidelines AND on increasing StO2 to 80% or more in at least 2 out of the 3 following sites: thenar, masseter and deltoid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: resuscitation will be based according to Surviving Sepsis Campaign
Study: NCT03673787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipatasertib
Description: Ipatasertib will be supplied as film-coated tablets in two strengths (100 and 200 mg) differentiated by size, shape, and weight of tablets. Ipatasertib tablets are packaged in high-density polyethylene bottles with desiccant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipatasertib
Description: Ipatasertib will be supplied as film-coated tablets in two strengths (100 and 200 mg) differentiated by size, shape, and weight of tablets. Ipatasertib tablets are packaged in high-density polyethylene bottles with desiccant.
Study: NCT01023230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Daily dosing starting approximately 4 weeks prior to first dose of DV-601 for one year total duration.
Study: NCT04378218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Description: A 16 week, 3 sessions per week HIIT program from the subject's personal wheelchair, positioned near an adjustable table with an arm-ergometer affixed.
Study: NCT00088985

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: 10 μg/kg subcutaneously (sc) each day for four days or g-CSF at 5 μg/kg sc each day for four days with GM-CSF 250 μg/m2 sc each day for four days. G-CSF and/or GM- CSF will be self-administered. On the fifth day patients will have two intravenous lines placed in the apheresis area of the Blood Bank and then undergo a 15 litre apheresis collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 4 mg/kg intravenously, every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine ditartrate
Description: Vinorelbine 25 mg/m2 will be administered intravenously, every 14 days
Study: NCT03673787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be supplied as a single-use 20 mL USP/Ph. Eur Type 1 glass vial as a colourless-to-slightly-yellow, sterile, preservative-free clear liquid solution intended for intravenous (IV) administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be supplied as a single-use 20 mL USP/Ph. Eur Type 1 glass vial as a colourless-to-slightly-yellow, sterile, preservative-free clear liquid solution intended for intravenous (IV) administration.
Study: NCT01595698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
Study: NCT01779102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-Tb
Description: C-Tb is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tuberculin PPD RT 23 SSI
Description: Tuberculin is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-Tb / Tuberculin PPD RT 23 SSI
Description: The C-Tb and Tuberculin agents are administered by the Mantoux injection technique to each volunteer in the RIGHT and LEFT forearm according to a double blind randomisation scheme
Study: NCT02654288

Intervention type: OTHER
Intervention: gemcitabine-based chemotherapy
Study: NCT00814190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Intervention
Description: The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
Study: NCT02518087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oXiris®
Description: oXiris® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication \[oXiris® (Baxter Gambro)\].~Blood flow between 200-250 mL/min will be derivatised from the CPB circuit (arterial positive pressure line just after the oxygenator) into the PrismafleX eXeed™, so that it all flows thru the oXiris® membrane and returned to the CPB circuit into the venous reservoir just before the oxygenator. oXiris® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time.
Study: NCT00864669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCl 500 mg tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under non-fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLUCOPHAGE® XR 500 mg tablets, single dose
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
Study: NCT01357135

Intervention type: DRUG
Intervention: Metformin

Intervention type: DRUG
Intervention: Metformin

Intervention type: DRUG
Intervention: Sitagliptin
Study: NCT01586676

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SAU
Description: Supervision-as-usual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIA: STEP
Description: Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP
Study: NCT03068130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl
Description: Capsules of Bardoxolone methyl
Study: NCT02515058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PUROS (Ridge Preservation bone grafting surgery)
Description: Ridge preservation bone grafting after tooth extraction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDBA (Ridge Preservation bone grafting surgery)
Description: Ridge preservation bone grafting after tooth extraction
Study: NCT00275054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: cycles 1-6: 25 mg/m² i.v., d2-4, q28d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cycles 1-6: 250 mg/m² i.v., d2-4, q28d

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: cycle1: 375 mg/m² i.v., d1, q28d~cycles 2-6: 500 mg/m² i.v., d1, q28d
Study: NCT03611764

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Scan
Description: -All efforts will be made to normalize their experience: for example, the desire to open their eyes, thinking about other things, wanting to move around - these are all normal and participants will be encouraged to become interested in and curious about, and to allow these natural tendencies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotterdam Symptom Checklist
Description: * 39 Likert-scale items, including physical and psychological symptoms (30 questions), daily function (8 questions), and overall valuation of life (one question)~* For the 30 questions pertaining to symptoms, the four-item Likert scale ranges from 'not at all=1' to 'very much=4'; the higher the total score, the greater the score, the higher the level of distress. The single question pertaining to overall valuation of life asks participants to circle one of the seven items, ranked from extremely poor to excellent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice Logs
Description: -Describe frequency of the Zen Den
Study: NCT01357135

Intervention type: DRUG
Intervention: Sulfonylurea

Intervention type: DRUG
Intervention: Antihyperglycemic Medication
Study: NCT01510145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% BAK-free
Description: Containing Polyquad (PQ) preservative
Study: NCT00617773

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hu3S193
Description: 20 mg/m2, intravenous, weekly for a maximum of 3 cycles (of 8 weeks each)
Study: NCT00836290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-Release (Group 1)
Description: Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-release (Group 2)
Description: Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
Study: NCT02425046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health coaching
Description: Health coaching using motivational interviewing focus on family diet and exercise change and connection with community resources specific to goals set.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: community screening
Description: Screening for community resources that families may be eligible for to receive help with basic needs including shelter, food, health insurance etc.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: community screening
Description: Screening for community resources that families may be eligible for to receive help with basic needs including shelter, food, health insurance etc.
Study: NCT02631174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithrombin III
Description: We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithrombin III
Description: We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithrombin III
Description: We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithrombin III
Description: We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume
Study: NCT03654170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809 mixed with [C-14] BI425809
Description: Oral Solution
Study: NCT03220074

Intervention type: DRUG
Group type: OTHER
Intervention: Oral Tablet
Description: study drug given and monitored for efficacy and tolerability
Study: NCT04207736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) dosed in the Environmental Exposure Chamber.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: Vehicle Ophthalmic Solution dosed in the Environmental Exposure Chamber.
Study: NCT02329704

Intervention type: PROCEDURE
Intervention: Diff-Quik staining for morphology evaluation
Description: Papanicolaou stain (haematoxylin, orange G6, and EA50) gives a clear difference between basophilic and acidophilic cell constituents and thereby enables a detailed examination of chromatin pattern, which is useful in the evaluation of sperm morphology and assessment of presence of immature spermatozoa. Cytoplasmic staining can vary between red and green dependent on ionic strength, pH, and composition of the cell department and the stain (OG6 and EA50).~Morphological assessment for processed portions of semen. As separation process has to minimize the morphological abnormal sperm.

Intervention type: PROCEDURE
Intervention: Diff-Quik staining for morphology evaluation
Description: Papanicolaou stain (haematoxylin, orange G6, and EA50) gives a clear difference between basophilic and acidophilic cell constituents and thereby enables a detailed examination of chromatin pattern, which is useful in the evaluation of sperm morphology and assessment of presence of immature spermatozoa. Cytoplasmic staining can vary between red and green dependent on ionic strength, pH, and composition of the cell department and the stain (OG6 and EA50).~Morphological assessment for processed portions of semen. As separation process has to minimize the morphological abnormal sperm.

Intervention type: PROCEDURE
Intervention: Motility Evaluation for grade A and B
Description: The better separation method will insure more progressive sperms after processing.~Grading using A and B scale scored by (WHO 2010) references.

Intervention type: PROCEDURE
Intervention: Motility Evaluation for grade A and B
Description: The better separation method will insure more progressive sperms after processing.~Grading using A and B scale scored by (WHO 2010) references.

Intervention type: PROCEDURE
Intervention: Concentration (mil/ml)
Description: count of isolated sperms Using Makler chamber for count of sperm for each portion post processing.
Study: NCT02833090

Intervention type: PROCEDURE
Group type: OTHER
Intervention: biomarkers
Description: transthoracic echocardiography, radial, and aortic arterial blood sampling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biomarkers
Description: transthoracic echocardiography, radial, and aortic arterial blood sampling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biomarkers
Description: transthoracic echocardiography, radial, and aortic arterial blood sampling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biomarkers
Description: transthoracic echocardiography, radial, and aortic arterial blood sampling
Study: NCT03424967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABM
Description: Participants are trained with a dot-probe task including angry-neutral faces. In 80% of trials the probe appears in place of the neutral face, and in 20% of trials in place of the angry face.
Study: NCT02272920

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: Medtronic Symplicity Flex, Medtronic Symplicity Spyral, or St Jude EnligHTN.
Study: NCT01529255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telbivudine (ROADMAP)
Description: Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA\<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial.
Study: NCT01368692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: position of shoulder retraction
Description: position of shoulder retraction by placing a saline bag between the scapula
Study: NCT02329704

Intervention type: PROCEDURE
Intervention: Concentration (mil/ml)
Description: count of isolated sperms Using Makler chamber for count of sperm for each portion post processing.

Intervention type: PROCEDURE
Intervention: 24 H half life
Description: percentage of active motile to non motile sperms.~Microscopic examination for each sample after 24 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile.

Intervention type: PROCEDURE
Intervention: 24 H half life
Description: percentage of active motile to non motile sperms.~Microscopic examination for each sample after 24 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile.

Intervention type: PROCEDURE
Intervention: 48 H half life
Description: percentage of active motile to non motile sperms.~Microscopic examination for each sample after 48 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile.

Intervention type: PROCEDURE
Intervention: 48 H half life
Description: percentage of active motile to non motile sperms.~Microscopic examination for each sample after 48 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile.
Study: NCT01368692

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: position of neutral shoulder
Description: neutral shoulder position during subclavian vein catheterization